| 210.9 1.18 (0.56%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 256.64 | 1-year : | 299.76 |
| Resists | First : | 219.72 | Second : | 256.64 |
| Pivot price | 208.82 |
|||
| Supports | First : | 206.89 | Second : | 198.96 |
| MAs | MA(5) : | 210.3  |
MA(20) : | 207.51 |
| MA(100) : | 206.18 |
MA(250) : | 210.62 |
|
| MACD | MACD : | 2.2 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 53.3 |
D(3) : | 51.7 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 234.08 | Low : | 191.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LH ] has closed below upper band by 39.9%. Bollinger Bands are 34.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 213.84 - 214.66 | 214.66 - 215.48 |
| Low: | 207.77 - 208.76 | 208.76 - 209.76 |
| Close: | 209.31 - 210.82 | 210.82 - 212.33 |
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Thu, 25 Jul 2024
Laboratory Co. of America Holdings (NYSE:LH) Announces Quarterly Dividend of $0.72 - MarketBeat
Thu, 25 Jul 2024
Labcorp Declares Quarterly Dividend - Marketscreener.com
Wed, 24 Jul 2024
Seven Eight Capital LP Acquires Shares of 5,917 Laboratory Co. of America Holdings (NYSE:LH) - MarketBeat
Mon, 22 Jul 2024
Avantax Advisory Services Inc. Purchases 97 Shares of Laboratory Co. of America Holdings (NYSE:LH) - Defense World
Sun, 21 Jul 2024
Tocqueville Asset Management L.P. Buys 200 Shares of Laboratory Co. of America Holdings (NYSE:LH) - Defense World
Mon, 20 May 2024
Labcorp Makes a Cosmetic Change - TheStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 84 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 96.8 (%) |
| Shares Short | 1,940 (K) |
| Shares Short P.Month | 2,340 (K) |
| EPS | 4.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 94.41 |
| Profit Margin | 3.5 % |
| Operating Margin | 10.1 % |
| Return on Assets (ttm) | 3.7 % |
| Return on Equity (ttm) | 4.3 % |
| Qtrly Rev. Growth | 4.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 145.92 |
| EBITDA (p.s.) | 19.21 |
| Qtrly Earnings Growth | 12.3 % |
| Operating Cash Flow | 1,280 (M) |
| Levered Free Cash Flow | 1,050 (M) |
| PE Ratio | 45.16 |
| PEG Ratio | 1.6 |
| Price to Book value | 2.23 |
| Price to Sales | 1.44 |
| Price to Cash Flow | 13.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|